Relationship of factor VIII and IX inhibitors with ABO Blood groups in patients with haemophilia A & B

Z BADIEI ,* A POURFATHOLLAH_ and H MANSOURITORGHABEH_

*Mashad Medical University, Ped Hem- Oncol Ward; _Hematology Group, Tarbiat Modares University, Tehran, Iran

Patient population: 150 patients included in this study: 102 patients with haemophilia A (43.1% had severe, 27.5% medium, and 29.4%

mild type, mean age 34.86 ± 14.75 years) and 48 patients with haemophilia B (48% patients with severe. 37.7% medium and 16.5% mild

type, mean age 21.35 ± 11.8 years). The patient population selected at random of northeastern of Iran.

Method: Whole blood specimens of 150 patients examined (102 haemophilia A patients [43.1% severe type] and 48 haemophilia B

patients [48% severe type]) for blood group serology and inhibitor level. Bethesda assay was evaluated according to references (10–12).

Factor IX and VIII deficient plasmas were prepared commercially (Diagnostica stago, France, Paris). Reference interval for inhibitor less

than 0.5 B.U. was calculated negative.

Results: Among 102 patients with haemophilia A., 20 patients (19.6%) had factor VIII inhibitor, with minimum and maximum titers of 0.8

and 6 B.U. respectively (mean 1.69 ± 1.32). In group with inhibitor, 19.4% had A group, 20.8% had B group, 20% had AB group, and

18.9% had O group. Among 48 haemophilia B patients, 3 patients (6.3%) had factor IX inhibitor. Minimum and maximum titers of

inhibitor were 0.8 and 1.8 B.U. respectively (mean 1.38 ± 0.46.). In group with inhibitor, 14.3% had A group, 9% had B group, none had

AB group, and 3.7% had O group. Chi-square tests showed there are no relationship between ABO blood groups and factor VIII

(P.V. = 0.998) and also IX inhibitor (P.V. = 0.7).

Conclusion: There are no relationships between ABO blood groups and factor VIII, also factor IX inhibitors.

INHIBITORS

_ 2006 Blackwell Publishing Ltd Haemophilia (2006), 12, (Suppl. 2)